In The News,
ADVI’s Vice President, Dr. Michael Kolodziej, talked to The American Journal of Managed Care about the side effects of first-gen BTK inhibitors
[el-text]
Written by Maggie L. Shaw
***excerpt***
“The thinking is that the reduced cardiovascular side effects, the reduced bleeding, are going to allow a better persistence on the second-generation drugs”
***end excerpt***
[/el-text]